Every material Form 8-K Charles River Laboratories filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Charles River reported third-quarter 2024 revenue of $1.01 billion, down 1.6% from a year earlier, with GAAP diluted EPS of $1.33, down 21.3%, and non-GAAP diluted EPS of $2.59, down 4.8%. The company raised its 2024 non-GAAP EPS guidance to $10.10-$10.30 from $9.90-$10.20 but cut its GAAP EPS guidance to $5.30-$5.50 from $5.65-$5.95, citing higher restructuring charges.
Q3 revenue $1.01 billion vs. $1.03 billion in Q3 2023; organic revenue declined 2.7%
GAAP diluted EPS $1.33 vs. $1.69; non-GAAP diluted EPS $2.59 vs. $2.72
2024 non-GAAP EPS guidance raised to $10.10-$10.30; GAAP EPS guidance cut to $5.30-$5.50
Board approved a $1.0 billion buyback on August 2, 2024; $899.3 million remained as of September 28, 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Charles River Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →